PathXchange, 24 and Objective pathology 23 that allow one to create an online digital slide collection that can be hosted on laboratory sites as supplementary data in articles. However, this approach is not widely recommended due to the transitory nature of the archive. 8, 25, 31 The importance of providing access to raw/supplemental data is reminiscent of the first stem cell microarray experiments published in 2002. 9, 12, 15, 27, 38 Two groups had independently identified and published lists of "stemness" genes in the same journal issue. This was followed by correspondences that consisted of meta-analyses and additional microarrays, which demonstrated the lack of concordance among the data sets. Thus, the public availability of such data uncovered the technical and biological challenges of identifying stemness genes.
In 2003, with the challenges of working with and analyzing large microarray data sets, publishers began to require standardization and deposition of microarray data into public repositories. 7, 13, 37 In the same year, the National Institutes of Health began requiring data sharing for large funded grants. 25 Presently, there are a number of public repositories for high-throughput gene expression data sets, such as the National Center for Biotechnology Information (NCBI), European Bioinformatics Institute, and DNA Data bank of Japan. 6, 10, 18, 34 The largest is the NCBI Gene Expression Omibus (GEO) (established in 2000), 1 which consists of over a billion individual measurements of high-throughput expression results from more than 100 organisms and a wide range of biological tissues. 22 To promote standardization for exchanging microarray data, the Functional Genomics Data Society developed guidelines for recording and reporting microarray data called the Minimum Information About a Microarray Experiment to ensure that the data can be easily interpreted and independently verified. 2, 21 Presently, the idea of having large data repositories from high-throughput expression data has expanded to include epigenomic and proteomic data sets. 11, 17, 30 The current standard for publication is to make raw microarray data available to the research community. Not only does this allow for outside confirmation and validation, but it allows the reader to judge the significance of the results by their own statistical methods. 25 Investigators can also use such data to develop and test data analysis and statistical validation algorithms. 4, 19, 25 The scientific community also benefits by sharing raw microarray data, allowing for meta-analysis-type experiments such as cross comparisons of independently generated but experimentally similar data sets, reanalysis, and reinterpretation providing insights into other fields, and increases the efficient use of funding and patient populations by avoiding duplicate experiments. 1, 3, 20, 25, 28, 29, 33, 37 Although preparing the data to deposit in a repository can be a time consuming process, Piwowar et al 25 showed that there are benefits to the investigator such as a higher citation rate.
Digital slides, also referred to as whole-slide images, are the product of scanning an entire glass slide into a digital image by whole-slide imaging (WSI) scanners. Their popularity and use are increasing due to the significantly improved scanning speed and image quality. Digital slides are very large data files, in which 1 slide/ image can vary from 200MB-1GB and contain approximately 100,000 Â 200,000 pixels (20 gigapixels). Each individual pixel represents the optical density at 3 separate wavelengths of a one-quarter micron square region of the original tissue section. Thus, one WSI contains more data than a typical next generation sequencing study. Therefore, digitization of all the glass studies involved in a clinical study, typically hundreds of slides, would result in enormous data sets. Thus, many of the current challenges of implementing digital slides into an experiment or study are analogous to those encountered earlier in incorporating microarray data in comparable settings, and many of the lessons learned by the microarray community could be applied to WSI and digital slide repositories.
There are many potential benefits of having a digital slide repository. It would allow for outside confirmation and validation of the entire slide/case/experiment rather than limiting and biasing the data to the selected fields of view that were photographed. WSI would better facilitate communication between the author and audience, along with elimination of selection bias, and allow more thorough validation by peer reviewers. Digital slides would also enable multiple perspectives and help identify potential errors in interpretation. Moreover, improved educational training and study opportunities would be enabled wherein an entire case could be reviewed and evaluated with digital slides, a "mock" sign-out of sorts.
In addition, providing access to digital slides in published biomarker studies that utilize in situ staining to evaluate new gene targets and/or use new probes would permit a comprehensive review of each case included in the study and provide more transparency and accuracy in the interpretation of such studies, assuring the reader that bias was not introduced based on selection of particular fields of view. We believe that this approach would provide more consistency and reliability in studies, possibly further improved by the addition of a quantitative component with image analysis (discussed below), which would benefit the scientific process.
With image analysis algorithms becoming more practical and popular, it will be possible to create reference data sets wherein the performance of different algorithms can be compared and contrasted, similar to approaches taken by Irizarry et al 14 for ribonucleic acid microarray data analysis algorithms. On their website, they have raw microarray data sets consisting of standardized dilutions and spike-ins that are publicly available. Algorithm developers can download the data sets, test their algorithms against it, and publicize the results as a series of performance measurements on their website. 5, 16 This allows evaluation of an algorithm's attributes and helps in choosing which method to use in a study.
Finally, having access to digital slides from clinical trials could serve as an important bridge between past, current, and future trials, for example, facilitating comparison of tissue responses among drugs. If these trials were complemented with histopathologic images, one would have an extremely valuable data set for morphology-based analysis to look for biomarkers and subtle similarities and differences in cellular responses to treatment. In addition, access to such digital slides of past and present clinical trials could serve as a discovery tool for bench researchers studying diseases, drug targets, and disease mechanisms. Finally, and perhaps most importantly, it would allow for more transparency and accuracy by allowing pathologists with varied experiences, backgrounds, and perspectives to evaluate the histopathologic changes associated with drug responses.
We believe that the implementation of this proposed image repository construct would benefit from a staged deployment, whereby the pathology community and the ultimate curation team (or teams) alike could effectively manage growth in terms of both operational complexity and volume. In early deployment phases, journal editors would have the option of requesting voluntary participation, such that WSI content corresponding to figures, accompanying article submissions, could be made available for reviewers in nonpublished screening areas, with such content not being available to the general public or journal audiences. On final acceptance and subsequent publication of said articles, these data could then be transferred to 1 or more permanent web-based repositories, so designed to ensure availability in perpetuity, thus facilitating the currently unmet dissemination need. Again, extrapolating on the operational wisdom already garnered in the microarray community, the next logical step would be to implement an expanded solution by which all constitutive histopathologic images of submitted studies are included in the collection of data that are ultimately to be digitized and made available on publication.
Although not all organizations currently have access to local digital slide scanning technology, the increasing availability of volume-based glass slide digitizing services from a plurality of contemporary WSI vendors can effectively mitigate this resource limitation. In this model, material submitted through mail and/or courier services can be quickly digitized and available for use (as was practiced in the initial adoption period of microarray technology, in which tissues or ribonucleic acid was sent to sites that would perform the microarray analysis and return raw and processed data).
Although the contemporary initial investment in locally situated WSI scanning technology can range from as little as $34,900 for low-volume devices to in excess of $400,000 for multidevice high-volume solutions that are tailored for large institutions, there exists an ever increasing repertoire of low-end solutions, suitable for deployment in both investigative units and clinical laboratories alike that provide images of suitably high quality. Even the least expensive of these solutions, such as a small form-factor $34,900 desktop scanner, is fully acceptable as a source for creation of referential grade WSI content, suitable for submission into repositories. By way of comparison, Bell's Law and Moore's Law have both accurately predicted the succession of improvements in performance and associated decreases in cost for computer technology, for the past several decades. Similarly, we can fully expect economies of scale in WSI technology to positively impact both price and performances, with ultimately instruments becoming fully commoditized, in a manner no different than the current reality for contemporary microscope technology.
For the succession of experiences in the microarray community that have led to the present, a critical point emerged in 2003 where funding agencies required investigators to make primary data available along with the publication of their manuscript. For the pathology experience, there will come a time in the near future when we should reasonably expect funding agencies to make similar demands for the submission of WSI content along with articles.
Given the enormous opportunities that could be afforded by public availability of whole-slide images, the various pathology organizations such as the College of American Pathologists, the United States Canadian Academy of Pathology, the National Cancer Institute, and NCBI-GEO would appear to be ideal stewards to host this content in perpetuity (as is already performed by NCBI-GEO). For example, the United States Canadian Academy of Pathology already asks presenters to provide digital slides from their presentations, and in addition, hosts this content for the benefit of their members. Independent of which organization or organizations ultimately end up being the designated or sanctioned hosts for this content, the extant service model as already espoused by NCBI-GEO would appear to be largely complete regarding pathology's needs, with minimal additions needed for it to start accepting submissions of WSI content. Should the NCBI-GEO repository ultimately not prove to be directly suitable, at the very least its architecture and its service model represent what is a very good starting point for the design of any new hosted constructs.
However, all the above efforts require proactive and immediate action on the part of the collective pathology communities. With such action, we should reasonably expect the myriad of benefits to trickle down to other areas of clinical medicine and biomedical research, with this transformation unambiguously benefiting the patient.
In conclusion, scanning the glass slides from published studies and entering them into a publicly available WSI repository would be of high value for both the pathologist and for broader scientific communities. They would also prove invaluable for quality control, pathologic assessment, and diagnostic verification for human biospecimens stored in research biorepositories nationally and internationally, allowing more confident sharing of comparable samples for scientific investigation and medical product development and validation. However, as with the development of gene expression microarray repositories, the process will need to be endorsed by scientific journals, editors, and, in this instance, the pathologists who appreciate the potential value offered by the advent of digital imaging and enhanced data storage capabilities.
